At the same time, the pooled analysis of different studies in the Oncomine database confirmed that compared with normal tissues, RCC1 is highly expressed in lung cancer, colorectal cancer, breast cancer, bladder cancer, brain cancer, sarcoma, prostate cancer, and leukemia (Supplementary Figure S4). Here, RCC1 is linked to prostate cancer.